Cevimeline hydrochloride. Treatment of Sjogran's syndrome muscarinic M1 and M2 agonist

Drugs of the Future

Volumn 25, Issue 6, 2000, Pages 558-562

  Sorbera, L A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEVIMELINE; LEVOFLOXACIN; PILOCARPINE; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; CARCINOGENESIS; CLINICAL TRIAL; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; MOLECULAR WEIGHT; NONHUMAN; REACTION ANALYSIS; REVIEW; SJOEGREN SYNDROME; THIN LAYER CHROMATOGRAPHY; XEROSTOMIA;

EID: 0343517636     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.06.583976     Document Type: Review

References (30)

1. Fisher, A., Heldman, E., Grunfeld, Y., Karton, I., Levy, A. (Israel Institute for Biological Research). Derivs. of quinuclidine. EP 0205247, JP 1986280497, US 4855290.
2. Hayashi, K., Tokumoto, S., Yoshizawa, H., Isogai, T. (Ishihara Sangyo Kaisha, Ltd.). Method for producing 2-methylspiro(1,3-oxathiolan-5,3')quinuclidine. EP 0683168, US 5571918.
3. Haga, T., Koyanagi, T., Hara, K., Maeda, M., Shigehara, I. (Ishihara Sangyo Kaisha, Ltd.). Method lor isomerization of trans-form 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine or acid addition salts thereof. EP 0298491, US 4861886.
4. Saito, K., Ono, T., Honda, N. (Snow Brand Milk Products Co., Ltd.). Preparation method of cis-2-methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride. 1/2 hydrate capable of disgregating easily. JP 1992108792.
5. Block, K.J., Buchanan, W.W., Wohl, M.J., Bunin, J.J. Sjögren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine 1965, 44: 187-231.
6. Dreizen, S., Brown, L.R., Daly, T.E., Drane, J.B. Prevention of xerostomia-related dental caries in irradiated cancer patients. J Dent Res 1977, 56: 99-104.
7. Pyykönen, H., Malmström, M., Oikarinen, V.J., Salmo, M., Vehkalahti. M. Late effects of radiation treatment of tongue and floor-of-mouth cancer on the dentition, saliva secretion, mucous membranes and lower jaw. Int J Oral Maxillofac Surg 1986, 15: 401-9.
8. Valdez, I.H., Atkinson, J.C., Ship, J.A., Fox, P.C. Major salivary gland function in patients with radiation-induced xerostomia: Flow rates and sialochemistry. Int J Radiat Oncol Biol Phys 1993, 25: 41-7.
9. Sreebny, L.M., Valdini, A. Xerostomia. A neglected symptom. Arch Intern Med 1987, 147: 1333-7.
10. Mandel, I.D. The functions of saliva. J Dent Res 1987, 66: 623-7.
11. Peters, N.L. Snipping the thread of life. Antimuscarinic side effects of medications in the elderly. Arch Intern Med 1989, 149: 2414-20.
12. Foster, H.E., Gilroy, J.J., Kelly, C.A., Howe, J., Griffiths, I.D. The treatment of sicca features in Sjögren's syndrome: A clinical review. Br J Rheumatol 1994, 33: 278-82.
13. Weaver, M.L., Tanzer, J.M., Kramer, P.A. Pilocarpine disposition and salivary flow responses following intravenous administration to dogs. Pharm Res 1992, 9: 1064-9.
14. Ciba Vision to market Salagen Tablets in Europe. DailyDrugNews.com (Daily Essentials) May 4, 2000.
15. Amarillo Biosciences reports phase III results for interferon alia in Sjögren's syndrome. DailyDrugNews.com (Daily Essentials) April 12, 2000.
16. 3 receptors. J Pharmacol Exp Ther 1987, 242: 257-62.
17. Iwabuchi, Y., Masuhara, T. Effects of cholinergic and adrenergic agonists on the secretion of fluid and protein by submandibular glands of the hamster and the rat. Comp Biochem Physiol C 1992,103: 277-83.
18. 3 muscarinic acetylcholine receptor coupling to PLC in rat exorbital lacrimal acinar cells. Am J Physiol 1993, 264: C1550-60.
19. 1 selective agonist AF102B (FKS-508). In: Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Disease, T. Nagatsu, A. Fisher and M. Yoshida (Eds.), Plenum Press, New York, 1990, 351-8.
20. Abe, N., Takeshita, Y. (Snow Brand Milk Products Co., Ltd.). Spirooxathiolane-quinuclidine deriv., for treating Sjögren syndrome. EP 0578511, US 5340821.
21. Handa, H., Takeshita, Y. (Snow Brand Milk Products Co., Ltd.). Spirooxathiolane-quinuclidine deriv. for the treatment of xerostomia. CA 2152420, EP 0689836, JP 1996012575, US 5580880.
22. Iga, Y., Arisawa, H., Ogane, N., Saito, Y., Tomizuka, T., Nakagawa-Yagi, Y., Masunaga, H., Yasuda, H., Miyata, N. (±)-cis-2-Methylspiro[1,3-oxathiolane-5,3'-quinuclidine]hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: The role of muscarinic acetylcholine receptors. Jpn J Pharmacol 1998, 78: 373-80.
23. Ninomiya, T., Iga, Y., Fukui, K., Arisawa, H., Uematsu, Y., Masunaga, H., Carman, M., Govier, W. The pharmacological profile of cevimeline (SNI-2011) - A novel muscarinic agonist for the treatment of xerostomia in various models. 62nd Annu Meet Am Coll Rheumatol (Nov 8-12, San Diego) 1998, Abst 1777.
24. Iwabuchi, Y., Masuhara, T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: Identification of a potential therapeutic agent for treatment of Sjögren's syndrome. Gen Pharmacol 1994, 25: 123-9.
25. Iwabuchi, Y., Katagiri, M., Masuhara, T. Salivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL/lpr mice. Arch Int Pharmacodyn Ther 1994, 328: 315-25.
26. Masunaga, H., Ogawa, H., Uematsu, Y., Tomizuka, T., Yasuda, H., Takeshita, Y. Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs. Eur J Pharmacol. 1997, 339: 1-9.
27. Ohtani, Y., Murasaki, M., Ishii, Y., Ishigooka, J., Miura, S. Phase 1 study of FKS-508 - Single and multiple dose studies. Eur J Pharmacol 1990, 183(3): Abst P.tu.412.
28. Evoxac™ Capsules Prescribing Information. FDA Web Site, Jan 19, 2000.
29. New hope for patients suffering from Sjögren's syndrome: FDA approves cevimeline. DailyDrugNews.com (Daily Essentials) April 26, 2000.
30. 3 muscarinic receptor agonist, for treatment of Sjögren's syndrome. 62nd Annu Meet Am Coll Rheumatol (Nov 8-12, San Diego) 1998, Abst 288.